Severe Hypertriglyceridemia in the Hospitalized Patient

  • Roselyn Cristelle I. Mateo
  • Om P. GandaEmail author


Hypertriglyceridemia (HTG) is prevalent and likely to increase multifold over the next few decades mostly due to the rising prevalence of obesity and diabetes mellitus (DM). One of the most untoward complications of severe HTG is acute pancreatitis (AP) requiring hospitalization for intensive treatment. The risk for AP is more clearly defined at triglyceride levels >1000 mg/dL. The prevention of HTG-associated AP requires a multifaceted approach with initiation of weight loss strategies, limiting fat and simple carbohydrates from diet, restriction of alcohol, control of secondary risk factors such as uncontrolled diabetes, discontinuation of offending medications as possible, and initiation of lipid-lowering medications. Pharmacologic options for very high TG include fibrates, niacin, and omega-3 polyunsaturated fatty acids (OM3FA), composed primarily of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). New agents that are not yet readily available, but have shown significant benefits, include the class of drugs known as the Apo CIII inhibitors. In patients with uncontrolled hyperglycemia, insulin with or without heparin can be very effective in the acute inpatient setting. In some studies, plasmapheresis has also been shown to be an effective modality for urgent lowering of TG levels.


Severe hypertriglyceridemia Acute pancreatitis associated with hypertriglyceridemia Familial syndromes of hypertriglyceridemia Hypertriglyceridemia secondary to medications Treatment of hypertriglyceridemia Omega-3 fatty acids Fibrates Niacin Apo CIII inhibitors 



OG was partially supported by NIDDK grant # P30-DK036836.

Suggested Readings

  1. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969–89.CrossRefGoogle Scholar
  2. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. REDUCE-IT investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.CrossRefGoogle Scholar
  3. Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11:352–62.CrossRefGoogle Scholar
  4. Chait A, Eckel RH. The Chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment of the chylomicronemia syndrome. Ann Intern Med. 2019;
  5. Jacobson TA, Maki KC, Orringer CE, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9:S1–122.CrossRefGoogle Scholar
  6. Nakhoda S, Zimrin AB, Baer MR, Law JY. Use of the APACHE II score to assess impact of therapeutic plasma exchange for critically ill patients with hypertriglyceride-induced pancreatitis. Transfus Apher Sci. 2017;56:123–6.CrossRefGoogle Scholar
  7. Rocha NA, East C, Zhang J, McCullough PA. ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen. Curr Atheroscler Rep. 2017;19:62.CrossRefGoogle Scholar
  8. Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48:195–203.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Joslin Diabetes Center, Department of Endocrinology, Beth Israel Deaconess Medical CenterBostonUSA
  2. 2.Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations